Sonidegib
- TRADE NAME: Odomzo (Novartis)
- INDICATIONS: Basal cell carcinoma
- CLASS: Hedgehog (Hh) signaling pathway inhibitor
- HALF-LIFE: 28 days
FDA APPROVAL DATE: 07/24/2015
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Atazanavir, Carbamazepine, Diltiazem, Efavirenz, Fluconazole, Itraconazole, Ketoconazole, Modafinil, Nefazodone, Phenobarbital, Phenytoin, Posaconazole, Rifabutin, Rifampin, Saquinavir, St John's Wort, Telithromycin, Voriconazole
PREGNANCY CATEGORY: N/A
Can cause fetal harm
Patients should not donate blood or blood products while receiving sonidegib and for at least 20 months after the last dose.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of sonidegib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/17/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
